Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821
Authors:
- 1 July 1999
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (7) , 2144
Abstract
PURPOSE: To describe quality-of-life considerations in postremission therapies for children with acute myelogenous leukemia. PATIENTS AND METHODS: A quality-adjusted survival analysis, using the quality-adjusted time without symptoms or toxicity (Q-TWiST) method, was applied to Pediatric Oncology Group Trial 8821, which compared randomized assignment with intensive consolidation chemotherapy (CC) or autologous bone marrow transplantation (ABMT). Nonrandomized assignment to allogeneic bone marrow transplantation (allo BMT) on the basis of availability of a matched related donor was also evaluated. A 25-patient cohort provided data for modeling chronic graft-versus-host disease. The Q-TWiST analysis was performed based on the intent-to-treat principle. RESULTS: As previously reported, the 3-year event-free survival was not significantly different between the randomized arms (CC v ABMT). At a median follow-up of 5 years (of the censoring distribution), the CC group had less time in toxicity (TOX) and more time without symptoms or toxicity (TWiST), relapse-free time, and alive time than patients assigned to ABMT (none of these were statistically significant). Compared with the CC group, allo BMT patients spent more time in TOX (P < .001), more time in TWiST (P = .06), and had more relapse-free time (P = .03) and time alive (P = .07). Allo BMT was superior to ABMT with greater time in TWiST (P = .02), relapse-free time (P = .01), and time alive P = .002). CONCLUSION: The Q-TWiST analysis is a powerful decision aid in choosing among alternative therapies. Prospective information on patient preferences will facilitate future trials evaluating treatment outcomes. Refinements in the Q-TWiST method could be included to further enhance the power of this patient care decision-making tool.Keywords
This publication has 34 references indexed in Scilit:
- A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal CancerJNCI: Journal of the National Cancer Institute, 1996
- Autologous Bone Marrow Transplantation versus Intensive Consolidation Chemotherapy for Acute Myeloid Leukemia in ChildhoodNew England Journal of Medicine, 1996
- Bone Marrow Transplantation for Children with Acute Myelogenous LeukemiaJournal of Pediatric Hematology/Oncology, 1995
- Comparing Treatments Using Quality-Adjusted Survival: The Q-TWiST MethodThe American Statistician, 1995
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Evaluation of the Quality of Life Associated with Zidovudine Treatment in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1994
- Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 casesBritish Journal of Haematology, 1989
- Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trialBritish Journal of Haematology, 1989
- Treatment of acute myelogenous leukemiaEuropean Journal of Cancer and Clinical Oncology, 1989
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983